Weizmann Institute of Science
Graduate-only public research university in Rehovot (founded 1934, renamed 1949), led by President Alon Chen across 276 research groups. Home to RSA co-inventor Adi Shamir and Yeda Research and Development, its tech-transfer arm, which manages ~500 patent families and has generated over $2 billion in royalties in a recent six-year period, mainly from Copaxone, Rebif and other Weizmann-origin drugs.
The Weizmann Institute of Science is a public research university in Rehovot, Israel, dedicated exclusively to graduate-level and postdoctoral research in the natural and exact sciences. Led by President Alon Chen and spanning 276 research groups, the institute's Yeda Research and Development technology-transfer arm generates the highest royalty income per researcher of any academic tech-transfer office worldwide.
Founding
The institute was established in 1934 as the Daniel Sieff Research Institute by Chaim Weizmann, a chemist who later became the first President of Israel, and renamed the Weizmann Institute of Science in 1949. Unlike Israeli universities that combine undergraduate and graduate education, Weizmann admits only graduate students (M.Sc. and Ph.D.) and postdoctoral fellows, allowing it to concentrate resources entirely on research output. As of the 2024-2025 academic year, the institute counted 1,801 students and postdocs, 276 principal investigators, and 2,599 total staff across 281 operating buildings on its 245-acre campus.
Research Impact
Weizmann researchers have won Nobel Prizes, Fields Medals and Turing Awards. The institute's contributions include foundational work in structural biology, particle physics, renewable energy, brain science and applied mathematics. Its Department of Computer Science and Applied Mathematics produced seminal contributions to cryptography, computational complexity and artificial intelligence; faculty member Adi Shamir co-invented the RSA encryption algorithm, the foundation of modern internet security. Weizmann scientists won 63 research prizes in 2025 alone and recorded a 62% success rate on European Research Council Starting Grants, more than five times the average among ERC member countries. The institute's BINA innovation unit, launched in 2021, had by late 2025 evaluated 156 early-stage research projects, approved 81 for funding and mentoring, and accelerated 19 into Yeda for commercialization.
Technology Transfer
Yeda Research and Development, the Weizmann Institute's technology-transfer arm since 1959, manages roughly 500 unique patent families and has generated more than $2 billion in royalty revenue over a recent six-year period, primarily from pharmaceutical patents, according to IsraelValley's reporting. About 80 to 90% of royalties trace to three inventions: the multiple sclerosis drug Copaxone, manufactured by Teva; Rebif, from Serono; and a satellite-broadcast encryption system from NDS. Yeda passes roughly 40% of royalties back to the inventing scientists, reinvesting the remainder in further research. Other drugs that trace to Weizmann discoveries include Erbitux, Humira, Enbrel, Remicade, Vectibix and the CAR-T cancer therapy Yescarta; in September 2025, Yeda signed an exclusive license agreement with Vyriad for a novel in vivo gene-delivery viral vector technology.
Funding Model
The Weizmann Institute is supported by a global network of "Friends of" organizations, including the American Committee for the Weizmann Institute, the Canadian Institute, and equivalents across Europe, Latin America and Asia, that collectively constitute one of the largest diaspora-funded academic endowments outside the United States. This fundraising architecture enables research independence and long-horizon science that is unusual for institutions of its size.
For a fuller institutional profile, including the Feinberg Graduate School, patent output, and the full list of Weizmann-origin pharmaceuticals, see The Weizmann Institute of Science: The Rehovot Basic-Research Institution Behind Copaxone, Rebif, Erbitux, and the Israeli Biomedical IP Base.